SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies.

Abstract

SAMITAL(®) (Indena SpA, Milan, Italy) is a new multicomponent and multiacting botanical formulation rationally designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in oncological patients. Each of the individual botanical constituents of SAMITAL-standardized extracts of Vaccinium myrtillus, Macleaya cordata and Echinacea angustifolia have a long history of clinical use that corroborates their safety and activity in SAMITAL. A number of pilot trials in oncological patients demonstrated that SAMITAL has good clinical efficacy and tolerability as evidenced by its significant effects in terms of reduction of mucositis, pain and a general improvement in patient quality of life. Importantly, the use of this botanical formulation had the added benefit that patients were able to complete their chemotherapy/radiotherapy regimen. Phase II trials with SAMITAL as part of an overall clinical development program are currently ongoing in Italy and are planned in the USA.

• Authors: Paolo Morazzoni, Giovanna Petrangolini, Ezio Bombardelli, Massimo Ronchi, Walter Cabri, Antonella Riva
• Journal: Future oncology (London, England) (Future Oncol) Vol. 9 Issue 11 Pg. 1717-25 (Nov 2013) ISSN: 1744-8301 [Electronic] England
• PMID: 24156331 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Plant Extracts
• samital

Topics

• Animals
• Antineoplastic Agents (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Head and Neck Neoplasms (drug therapy, radiotherapy)
• Humans
• Mucositis (chemically induced, drug therapy)
• Plant Extracts (therapeutic use)
• Quality of Life
• Radiation Injuries (drug therapy)